secwatch / observer
8-K filed February 29, 2024, 6:59 PM ET ticker NUTX CIK 0001479681
leadership confidence high sentiment neutral materiality 0.30

Nutex Health director Dr. Danniel Stites to depart; Dr. Kelvin Spears appointed

Nutex Health Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Danniel Stites

Director
NUTX · Nutex Health Inc.
Effective
2024-04-01
Successor
Dr. Kelvin Spears
Filed
February 29, 2024, 6:59 PM ET
Dr. Danniel Stites informed the Board of Directors (the “Board”) of Nutex Health Inc. (the “Company”) that he had decided to depart from the Board at the end of his one year term commitment which had commenced on April 1, 2023.
Appointed

Dr. Kelvin Spears

Director
NUTX · Nutex Health Inc.
Effective
2024-04-01
Filed
February 29, 2024, 6:59 PM ET
On February 28, 2024, the Board elected Dr. Kelvin Spears, 63, as a member of the Board effective April 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Danniel Stites departed as Director at Nutex Health Inc..

Action
depart
Role
Director
Exact text from the filing
Dr. Danniel Stites informed the Board of Directors (the “Board”) of Nutex Health Inc. (the “Company”) that he had decided to depart from the Board at the end of his one year term commitment which had commenced on April 1, 2023.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Kelvin Spears was elected as Director at Nutex Health Inc..

Action
elected
Role
Director
Exact text from the filing
On February 28, 2024, the Board elected Dr. Kelvin Spears, 63, as a member of the Board effective April 1, 2024.
View on SEC.gov

Nutex Health Inc. filing history →

Source: SEC EDGAR
accession 0001558370-24-002198
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.